In a population of non-small cell lung cancer patients, more than 50% of the patients with PD according to the PET Response Criteria in Solid Tumors (PERCIST) on interim PET/CT (7 weeks after initiation of anti-PD1 mAb treatment with pembrolizumab or nivolumab) that continued the ICI treatment had a response or stable disease (SD) on the following PET/CT, defining pseudoprogression (48). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.